top of page

Leibniz IPHT leads an european cross-laboratory study to bring RAMAN spectroscopy to the clinic

Updated: Jun 21, 2021

Is the tissue healthy or pathologically altered? Is the antibiotic effective against a certain bacterium or is the bacterium resistant to it? Raman spectroscopy can help to answer such questions quickly and precisely. However, one challenge for the use of the light-based analysis method in everyday clinical practice is that the results can be highly sensitive to the measurement conditions. Approaches to solving this problem are now being provided by a large-scale European cross-laboratory study led by Leibniz IPHT.


A decisive step towards common standards and thus a practical application of Raman spectroscopy would be that both researchers and spectrometer manufacturers make data publicly available, recommends the research team. The study was published in the journal Analytical Chemistry.


To raise awareness of this challenge, 86 researchers from 15 institutions in seven European countries put the comparability of Raman spectroscopic instruments with different configurations to the test. The European Union funded the Raman4Clinics initiative, launched by Leibniz IPHT, as a COST (European Cooperation in Science and Technology) Action. „With the largest cross-laboratory study of Raman spectroscopy experiments to date, the study is an important step toward bringing Raman spectroscopy into clinical applications“, says Prof. Jürgen Popp, scientific director of Leibniz IPHT and spokesman for the "Raman4Clinics" consortium.


The "Raman4Clinics" team concludes with a clear recommendation to both spectrometer manufacturers and the scientific community of Raman spectroscopy. "Manufacturers and scientists should calibrate the spectrometer as standard and make the corresponding software modules available open-source," says Thomas Bocklitz. This, he says, is a viable and attractive first step to correct for the influence of measurement-related effects on Raman signals.


After the research team has studied simple substances such as polystyrene and paracetamol, it is now starting to investigate complex biological samples. The results will be incorporated into the National Research Data Infrastructure (NFDI). This networked structure, funded by the German Research Foundation (DFG), is designed to systematically develop, sustainably secure and make accessible the data holdings of science and research.


22 views0 comments
bottom of page